Top

06-16-2018 | Medications | Review | Article

Availability and Affordability of Essential Medicines: Implications for Global Diabetes Treatment

Journal: Current Diabetes Reports

Authors: David Beran, Margaret Ewen, Kasia Lipska, Irl B. Hirsch, John S. Yudkin

Abstract

Purpose of Review

The purpose of this review is to highlight the key issues with regard to the value, affordability, and availability of diabetes treatments.

Recent Findings

Many of the medicines needed to manage diabetes are available as generics and, if purchased appropriately, can be made affordable to many individuals and systems. With new treatments for diabetes, additional costs to individuals and systems need to be assessed in terms of added clinical benefit and financial impact. As healthcare finances are limited, increased spending on diabetes medicines means fewer resources for other areas of diabetes care or for the population as a whole. This increased expenditure is driven by rising prevalence as well as the cost of newer treatments.

Summary

With an increasing burden of disease and changing patterns of medicines in the market, we stress the need to focus attention on ensuring access for individuals to essential medicines. Universal health care offers unique opportunity to address the issue of access to medicines and the wider issues surrounding access to diabetes care, but this will require concerted action bringing together governments, civil society and the private sector.

WHO. Essential medicines and health products. Geneva: World Health Organization; 2018. http://www.who.int/medicines/services/essmedicines_def/en/. Accessed 24 February 2018

WHO. 20th Model List of Essential Medicines. Geneva: World Health Organization; 2017.

WHO Collaborating Centre for Drug Statistics Methodology. Drugs used in diabetes. Oslo: Norwegian Institute of Public Health; 2018. http://www.whocc.no/atc_ddd_index/?code=A10A. Accessed 6 February 2018

•• Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol. 2016; https://doi.org/10.1016/S2213-8587(15)00521-5. This paper gives a comprehensive overview of the global challenges of access to insulin.

Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings. Diabetes Res Clin Pract. 2010;88(3):217–21. https://doi.org/10.1016/j.diabres.2010.03.029.CrossRefPubMed

Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240–9. https://doi.org/10.1016/S0140-6736(08)61762-6.CrossRefPubMed

Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA. 2014;311(22):2331–3. https://doi.org/10.1001/jama.2014.6316.CrossRefPubMedPubMedCentral

Tylee T, Hirsch IB. Costs associated with using different insulin preparations. JAMA. 2015;314(7):665–6. https://doi.org/10.1001/jama.2015.7032.CrossRefPubMed

Currie CJ, Gale EA, Poole CD. Estimation of primary care treatment costs and treatment efficacy for people with type 1 and type 2 diabetes in the United Kingdom from 1997 to 2007. Diabet Med. 2010;27(8):938–48. https://doi.org/10.1111/j.1464-5491.2010.03040.x.CrossRefPubMed

10.

IDF. International Diabetes Federation Diabetes Atlas. 8th ed. Brussels: International Diabetes Federation; 2017.

11.

Ministère de la solidarités et de la santé. Base de données publique des médicaments. Ministère de la solidarités et de la santé. 2018. http://base-donnees-publique.medicaments.gouv.fr/index.php#result. Accessed 19 February 2018.

12.

Diabetes Canada. Approximate cost reference list for antihyperglycemic agents. Diabetes Canada. 2016. http://guidelines.diabetes.ca/browse/appendices/appendix5_2016. Accessed 19 February 2018.

13.

Bundesamt für Gesundheit. Spezialitätenliste. 2017. https://www.spezialitatenliste.ch. Accessed 19 February 2018.

14.

Joint Formulary Committee. British national formulary 70, vol. 2016. London: BMJ Publishing and the Royal Pharmaceutical Society.

15.

McEwen LN, Casagrande SS, Kuo S, Herman WH. Why are diabetes medications so expensive and what can be done to control their cost? Curr Diab Rep. 2017;17(9):71. https://doi.org/10.1007/s11892-017-0893-0. CrossRefPubMed

16.

IQWiG. Medicine put to the test. Institute for Quality and Efficiency in Health Care Koln. 2017. https://www.iqwig.de/en/home.2724.html. Accessed 12 February 2018.

17.

NICE. What we do. National Institute for Health and Clinical Excellence London. 2018. https://www.nice.org.uk/get-involved/contact-us. Accessed 10 February 2018.

18.

Bach PB. New math on drug cost-effectiveness. N Engl J Med. 2015;373(19):1797–9. https://doi.org/10.1056/NEJMp1512750.CrossRefPubMed

19.

Sakulsupsiri A, Sakthong P, Winit-Watjana W. Cost-effectiveness analysis of the self-management program for Thai patients with metabolic syndrome. Value Health Reg Issues. 2016;9:28–35. https://doi.org/10.1016/j.vhri.2015.10.004.CrossRefPubMed

20.

WHO. The selection and use of essential medicines: report of the WHO Expert Committee, March 2011 (including the 17th WHO model list of essential medicines and the 3rd WHO model list of essential medicines for children). Geneva: World Health Organization; 2011.

21.

WHO. Report of the 21st WHO Expert Committee on the Selection and Use of Essential Medicines. Geneva: World Health Organization; 2017.

22.

Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;(6):CD012161. https://doi.org/10.1002/14651858.CD012161.

23.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;(2):CD005613. https://doi.org/10.1002/14651858.CD005613.pub3.

24.

Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006;(2):CD003287. https://doi.org/10.1002/14651858.CD003287.pub4.

25.

Riddle MC. Lessons from peglispro: IMAGINE how to improve drug development and affordability. Diabetes Care. 2016;39(4):499–501. https://doi.org/10.2337/dc15-2754.CrossRefPubMed

26.

Gill GV, Yudkin JS, Keen H, Beran D. The insulin dilemma in resource-limited countries. A way forward? Diabetologia. 2011;54(1):19–24. https://doi.org/10.1007/s00125-010-1897-3.CrossRefPubMed

27.

Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. London: LSE Health, London School of Economics; 2012.

28.

NHS Digital. Prescribing for Diabetes, England-2005/06 to 2015/2016. London: National Health Service, UK; 2016. https://digital.nhs.uk/catalogue/PUB21158. Accessed 24 February 2018

29.

Luo J, Kesselheim AS, Greene J, Lipska KJ. Strategies to improve the affordability of insulin in the USA. Lancet Diabetes Endocrinol. 2017;5(3):158–9. https://doi.org/10.1016/S2213-8587(17)30041-4.CrossRefPubMed

30.

Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW. Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care. 2015;38(4):581–7. https://doi.org/10.2337/dc14-1687. PubMedCrossRef

31.

WHO and HAI. Measuring medicine prices, availability, affordability and price components. Geneva: World Health Organization and Health Action International; 2008.

32.

Sharma A, Kaplan WA. Challenges constraining access to insulin in the private-sector market of Delhi, India. BMJ Glob Health. 2016;1(3):e000112. https://doi.org/10.1136/bmjgh-2016-000112.CrossRefPubMedPubMedCentral

33.

Shrestha R, Ghale A, Chapagain BR, Gyawali M, Acharya T. Survey on the availability, price and affordability of selected essential medicines for non-communicable diseases in community pharmacies of Kathmandu valley. SAGE Open Med. 2017;5:2050312117738691. https://doi.org/10.1177/2050312117738691. CrossRefPubMedPubMedCentral

34.

Jingi AM, Noubiap JJ, Ewane Onana A, Nansseu JR, Wang B, Kingue S, et al. Access to diagnostic tests and essential medicines for cardiovascular diseases and diabetes care: cost, availability and affordability in the West Region of Cameroon. PLoS One. 2014;9(11):e111812. https://doi.org/10.1371/journal.pone.0111812.CrossRefPubMedPubMedCentral

35.

Kibirige D, Atuhe D, Kampiire L, Kiggundu DS, Donggo P, Nabbaale J, et al. Access to medicines and diagnostic tests integral in the management of diabetes mellitus and cardiovascular diseases in Uganda: insights from the ACCODAD study. Int J Equity Health. 2017;16(1):154. https://doi.org/10.1186/s12939-017-0651-6. CrossRefPubMedPubMedCentral

36.

Dabare PR, Wanigatunge CA, Beneragama BH. A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka. BMC Public Health. 2014;14:817. https://doi.org/10.1186/1471-2458-14-817.CrossRefPubMedPubMedCentral

37.

Liu C, Zhang X, Liu C, Ewen M, Zhang Z, Liu G. Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China. BMC Health Serv Res. 2017;17(1):597. https://doi.org/10.1186/s12913-017-2553-0. CrossRefPubMedPubMedCentral

38.

Ewen M, Joose H, Ashigbie P, Beran D, Laing R. Insulin prices profile. Amsterdam: Health Action International; 2016.

39.

Beran D, Yudkin J, de Courten M. Access to care for patients with insulin-requiring diabetes in developing countries: case studies of Mozambique and Zambia. Diabetes Care. 2005;28(9):2136–40.CrossRefPubMed

40.

Beran D, Abdraimova A, Akkazieva B, McKee M, Balabanova D, Yudkin JS. Diabetes in Kyrgyzstan: changes between 2002 and 2009. Int J Health Plann Manag. 2012;28:e121–37. https://doi.org/10.1002/hpm.2145.CrossRef

41.

WHO. Health statistics and information systems. Geneva: World Health Organization; 2018. http://www.who.int/healthinfo/systems/sara_methods/en/. Accessed 10 February 2018

42.

Peck R, Mghamba J, Vanobberghen F, Kavishe B, Rugarabamu V, Smeeth L, et al. Preparedness of Tanzanian health facilities for outpatient primary care of hypertension and diabetes: a cross-sectional survey. Lancet Glob Health. 2014;2(5):e285–e92. https://doi.org/10.1016/S2214-109X(14)70033-6. CrossRefPubMedPubMedCentral

43.

Nyarko KM, Ameme DK, Ocansey D, Commeh E, Markwei MT, Ohene SA. Capacity assessment of selected health care facilities for the pilot implementation of package for essential non-communicable diseases (PEN) intervention in Ghana. Pan Afr Med J. 2016;25(Suppl 1):16. https://doi.org/10.11604/pamj.supp.2016.25.1.6252.PubMedPubMedCentralCrossRef

44.

Mendis S, Al Bashir I, Dissanayake L, Varghese C, Fadhil I, Marhe E, et al. Gaps in capacity in primary care in low-resource settings for implementation of essential noncommunicable disease interventions. Int J Hypertens. 2012;2012:584041. https://doi.org/10.1155/2012/584041.CrossRefPubMedPubMedCentral

45.

Beran D, Abdraimova A, Akkazieva B, McKee M, Balabanova D, Yudkin JS. Diabetes in Kyrgyzstan: changes between 2002 and 2009. Int J Health Plann Manag. 2013;28(2):e121–37. https://doi.org/10.1002/hpm.2145.CrossRef

46.

Beran D, Higuchi M. Delivering diabetes care in the Philippines and Vietnam: policy and practice issues. Asia Pac J Public Health. 2013;25(1):92–101. https://doi.org/10.1177/1010539511412177.CrossRefPubMed

47.

Beran D, Silva Matos C, Yudkin JS. The Diabetes UK Mozambique twinning Programme. Results of improvements in diabetes care in Mozambique: a reassessment 6 years later using the rapid assessment protocol for insulin access. Diabet Med. 2010;27(8):855–61. https://doi.org/10.1111/j.1464-5491.2010.03053.x.CrossRefPubMed

48.

HAI. Database of medicine prices, availability, affordability and price components. 2012. http://www.haiweb.org/MedPriceDatabase/. Accessed 9 July 2015.

49.

Gaskin DJ, Thorpe RJ Jr, McGinty EE, Bower K, Rohde C, Young JH, et al. Disparities in diabetes: the nexus of race, poverty, and place. Am J Public Health. 2014;104(11):2147–55. https://doi.org/10.2105/AJPH.2013.301420.CrossRefPubMedPubMedCentral

50.

Islam NS, Kwon SC, Wyatt LC, Ruddock C, Horowitz CR, Devia C, et al. Disparities in diabetes management in Asian Americans in New York City compared with other racial/ethnic minority groups. Am J Public Health. 2015;105(Suppl 3):S443–6. https://doi.org/10.2105/AJPH.2014.302523.CrossRefPubMedPubMedCentral

51.

Hale NL, Bennett KJ, Probst JC. Diabetes care and outcomes: disparities across rural America. J Community Health. 2010;35(4):365–74. https://doi.org/10.1007/s10900-010-9259-0.CrossRefPubMed

52.

Simmons D, Bourke L, Yau E, Hoodless M. Diabetes risk factors, diabetes and diabetes care in a rural Australian community. Aust J Rural Health. 2007;15(5):296–303. https://doi.org/10.1111/j.1440-1584.2007.00903.x.CrossRefPubMed

53.

Beckett M, Firestone MA, McKnight CD, Smylie J, Rotondi MA. A cross-sectional analysis of the relationship between diabetes and health access barriers in an urban first nations population in Canada. BMJ Open. 2018;8(1):e018272. https://doi.org/10.1136/bmjopen-2017-018272.CrossRefPubMedPubMedCentral

54.

Beyerlein A, Koller D, Ziegler AG, Lack N, Maier W. Does charge-free screening improve detection of gestational diabetes in women from deprived areas: a cross-sectional study. BMC Pregnancy Childbirth. 2016;16:266. https://doi.org/10.1186/s12884-016-1060-3.CrossRefPubMedPubMedCentral

55.

Vanasse A, Courteau J, Cohen AA, Orzanco MG, Drouin C. Rural-urban disparities in the management and health issues of chronic diseases in Quebec (Canada) in the early 2000s. Rural Remote Health. 2010;10(4):1548.PubMed

56.

•• Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: an effective, less-expensive option. JAMA. 2017;318(1):23–4. https://doi.org/10.1001/jama.2017.6939. A very interesting and useful publication for healthcare providers on insulin and its use. CrossRefPubMed

57.

Hunter M. Doctors worried about threat to supplies of animal insulin. BMJ. 2002;324(7330):130.CrossRefPubMedPubMedCentral

58.

Mixtard 30—going, going, gone? Drug Ther Bull. 2010;48(8):85. https://doi.org/10.1136/dtb.2010.08.0040.

59.

Perrin C, Ewen M, Beran D. The role of biosimilar manufacturers in improving access to insulin globally. Lancet Diab Endocrinol. 2017;5:578. https://doi.org/10.1016/S2213-8587(17)30218-8.CrossRef

60.

Wirtz V. Insulin market profile. Amsterdam: Health Action International; 2016.

61.

Beran D, Binh TV, Khue NT, Uoc HK, Toan LQ, Phuong NB, et al. Report on the Rapid Assessment Protocol for Insulin Access in Vietnam. London: International Insulin Foundation; 2009.

62.

Cardenas MK, Miranda JJ, Beran D. Delivery of type 2 diabetes care in low- and middle-income countries: lessons from Lima, Peru. Diabet Med. 2016;33(6):752–60. https://doi.org/10.1111/dme.13099.CrossRefPubMed

63.

Beran D. Improving access to insulin: what can be done? Diabetes Manag. 2011;1(1):67–76.

64.

Jones T. Diabetes mellitus: the increasing burden of disease in Kenya. SSMJ. 2013;6(3)

65.

Beran D. The Diabetes Foundation Report on implementing national diabetes programmes in sub-Saharan Africa. London: International Insulin Foundation; 2006.

66.

•• Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002–2013. JAMA. 2016;315(13):1400–2. https://doi.org/10.1001/jama.2016.0126. Provides a detailed perspective on spending on diabetes medicines in the USA. CrossRefPubMedPubMedCentral

67.

• Lipska KJ, Yao X, Herrin J, McCoy RG, Ross JS, Steinman MA, et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013. Diabetes Care. 2017;40(4):468–75. https://doi.org/10.2337/dc16-0985. Highlights changes in use of medicines for diabetes and links these with outcomes. CrossRefPubMed

68.

• Basu S, Sussman JB, Berkowitz SA, Hayward RA, Bertoni AG, Correa A, et al. Validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from diverse longitudinal cohorts in the US. Diabetes Care. 2018;41(3):586–95. https://doi.org/10.2337/dc17-2002. Presents a model looking at diabetes-related outcomes and risks. CrossRefPubMed

69.

Oanda. Currency Converter. 2018. https://www.oanda.com/currency/converter/. Accessed 19 February 2018.

70.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–32. https://doi.org/10.1056/NEJMoa1615692.CrossRefPubMedPubMedCentral

71.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

72.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

73.

Currie CJ, Peters JR, Evans M. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. Diabet Med. 2010;27(7):744–52. https://doi.org/10.1111/j.1464-5491.2009.02849.x.CrossRefPubMed

74.

Ko SH, Kim DJ, Park JH, Park CY, Jung CH, Kwon HS, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study. Medicine (Baltimore). 2016;95(27):e4018. https://doi.org/10.1097/MD.0000000000004018.CrossRef

75.

Sliwczynski A, Brzozowska M, Jacyna A, Iltchev P, Iwanczuk T, Wierzba W, et al. Drug-class-specific changes in the volume and cost of antidiabetic medications in Poland between 2012 and 2015. PLoS One. 2017;12(6):e0178764. https://doi.org/10.1371/journal.pone.0178764.CrossRefPubMedPubMedCentral

76.

Flood D, Mathieu I, Chary A, Garcia P, Rohloff P. Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff. BMC Health Serv Res. 2017;17(1):27. https://doi.org/10.1186/s12913-017-1991-z. CrossRefPubMedPubMedCentral

77.

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016;10:1299–307. https://doi.org/10.2147/PPA.S106821.CrossRefPubMedPubMedCentral

78.

Kirkman MS, Rowan-Martin MT, Levin R, Fonseca VA, Schmittdiel JA, Herman WH, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604–9. https://doi.org/10.2337/dc14-2098. PubMedPubMedCentralCrossRef

79.

Awodele O, Osuolale JA. Medication adherence in type 2 diabetes patients: study of patients in Alimosho General Hospital, Igando, Lagos, Nigeria. Afr Health Sci. 2015;15(2):513–22. https://doi.org/10.4314/ahs.v15i2.26.CrossRefPubMedPubMedCentral

80.

Pihau-Tulo ST, Parsons RW, Hughes JD. An evaluation of patients' adherence with hypoglycemic medications among Papua New Guineans with type 2 diabetes: influencing factors. Patient Prefer Adherence. 2014;8:1229–37. https://doi.org/10.2147/PPA.S66655.CrossRefPubMedPubMedCentral

81.

Abebe SM, Berhane Y, Worku A. Barriers to diabetes medication adherence in North West Ethiopia. Springerplus. 2014;3:195. https://doi.org/10.1186/2193-1801-3-195.CrossRefPubMedPubMedCentral

82.

Bibeau WS, Fu H, Taylor AD, Kwan AY. Impact of out-of-pocket pharmacy costs on branded medication adherence among patients with type 2 diabetes. J Manag Care Spec Pharm. 2016;22(11):1338–47. https://doi.org/10.18553/jmcp.2016.22.11.1338.CrossRefPubMed

83.

Metta E, Haisma H, Kessy F, Geubbels E, Hutter I, Bailey A. “It is the medicines that keep us alive”: lived experiences of diabetes medication use and continuity among adults in southeastern Tanzania. BMC Health Serv Res. 2015;15:111. https://doi.org/10.1186/s12913-015-0768-5.CrossRefPubMedPubMedCentral

84.

Life for a Child. Life for a Child. 2018. https://www.lifeforachild.org. Accessed 11 February 2018.

85.

Insulin for Life. Insulin for Life. 2018. https://www.insulinforlife.org. Accessed 11 February 2018.

86.

Novo Nordisk. Novo Nordisk Annual Report 2017: Novo Nordisk; 2017.

87.

Novo Nordisk. Changing Diabetes in Children. 2018. https://www.novonordisk.com/sustainable-business/performance-on-tbl/access-to-care/changing-diabetes-in-children.html. Accessed 11 February 2018.

88.

Novo Nordisk. Reaching the base of the pyramid in Kenya: Novo Nordisk; 2014.

89.

Beran D. The impact of health systems on diabetes care in low and lower middle income countries. Curr Diab Rep. 2015;15(4):20. https://doi.org/10.1007/s11892-015-0591-8. CrossRefPubMed

90.

WHO. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. Geneva: World Health Organization; 2013.

91.

Ewen M, Zweekhorst M, Regeer B, Laing R. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS One. 2017;12(2):e0171284. https://doi.org/10.1371/journal.pone.0171284.CrossRefPubMedPubMedCentral

92.

Robertson J, Mace C, Forte G, de Joncheere K, Beran D. Medicines availability for non-communicable diseases: the case for standardized monitoring. Glob Health. 2015;11(1):18. https://doi.org/10.1186/s12992-015-0105-0. CrossRef

93.

Niens LM, Brouwer WB. Measuring the affordability of medicines: importance and challenges. Health Policy. 2013;112(1–2):45–52. https://doi.org/10.1016/j.healthpol.2013.05.018.CrossRefPubMed

94.

Niens LM, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer WB. Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012;90(3):219–27. https://doi.org/10.2471/BLT.10.084087.CrossRefPubMedPubMedCentral

95.

Frost LJ, Reich MR. Access: how do good health technologies get to poor people in poor countries. Cambridge: Harvard Center for Population and Development Studies; 2008.

96.

WHO. The World Health Report 2010: Health system financing: the path to universal coverage. Geneva: World Health Organization; 2010.

97.

WHO. Global status report on noncommunicable diseases. Geneva: World Health Organization; 2010.

98.

WHO. All roads lead to universal health coverage. Geneva: World Health Organization; 2017. http://www.who.int/mediacentre/commentaries/2017/universal-health-coverage/en/. Accessed 19 February 2018

99.

WHO. Director-General Dr Tedros takes the helm of WHO: address to WHO staff. Geneva: World Health Organization; 2017. http://www.who.int/dg/speeches/2017/taking-helm-who/en/. Accessed 19 February 2018

100.

Beran D, Hirsch I, Yudkin J. Why are we failing to address the issue of access to insulin? A national and global perspective. Diabetes Care. 2018;41(6):1125-1131. https://doi.org/10.2337/dc17-2123.

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform.

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »